Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/15/2025 | $135.00 | Neutral → Buy | Roth Capital |
| 12/17/2024 | $125.00 → $128.00 | Neutral → Overweight | Analyst |
| 9/10/2024 | Peer Perform | Wolfe Research | |
| 7/1/2024 | $140.00 → $115.00 | Overweight → Neutral | Piper Sandler |
| 5/30/2024 | $129.00 | Neutral | Goldman |
| 5/21/2024 | $150.00 | Hold → Buy | Argus |
| 1/4/2024 | $135.00 → $125.00 | Outperform → In-line | Evercore ISI |
| 10/20/2023 | $120.00 | Neutral | ROTH MKM |
8-K - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)
SCHEDULE 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
10-Q - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)
WARSAW, Ind., Sept. 4, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced its participation in the American Orthopedic Foot and Ankle Society Annual Conference in Savannah, Ga. From September 10-13, 2025, Zimmer Biomet's wholly owned subsidiary, Paragon 28, will feature a suite of industry-leading foot and ankle products. "We are excited to engage with foot and ankle specialists at AOFAS and highlight our latest innovations in what's been a remarkably strong cadence of product launches over the past two ye
Dr. Jonathan M. Vigdorchik Named Chief Medical Technology Advisor, Adult Reconstruction and Hip Implants Dr. Anand M. Murthi Appointed Chief Medical Advisor, Shoulder, Sports, Extremities, and Trauma (S.E.T.) WARSAW, Ind., Aug. 28, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointments of Jonathan M. Vigdorchik, MD, as Chief Medical Technology Advisor focused on Adult Reconstruction and Hip Implants, and Anand M. Murthi, MD, FAAOS, as Chief Medical Advisor, Shoulder, Sports, Extremities, and Trauma (S.E.T.). As strategic advisors, Drs. Vigdorchik and Murthi will leverage their extensive clinical experience t
WARSAW, Ind., Aug. 27, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2025. The cash dividend of $0.24 per share is payable on or about October 31, 2025 to stockholders of record as of the close of business on September 30, 2025. About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health.
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
Roth Capital upgraded Zimmer Biomet from Neutral to Buy and set a new price target of $135.00
Analyst upgraded Zimmer Biomet from Neutral to Overweight and set a new price target of $128.00 from $125.00 previously
Wolfe Research initiated coverage of Zimmer Biomet with a rating of Peer Perform
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
Dr. Jonathan M. Vigdorchik Named Chief Medical Technology Advisor, Adult Reconstruction and Hip Implants Dr. Anand M. Murthi Appointed Chief Medical Advisor, Shoulder, Sports, Extremities, and Trauma (S.E.T.) WARSAW, Ind., Aug. 28, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointments of Jonathan M. Vigdorchik, MD, as Chief Medical Technology Advisor focused on Adult Reconstruction and Hip Implants, and Anand M. Murthi, MD, FAAOS, as Chief Medical Advisor, Shoulder, Sports, Extremities, and Trauma (S.E.T.). As strategic advisors, Drs. Vigdorchik and Murthi will leverage their extensive clinical experience t
WARSAW, Ind., May 27, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Kevin Thornal as Group President, Global Businesses and the Americas. Reporting to Chairman-Elect, President and CEO Ivan Tornos, Mr. Thornal will join the Company on July 1, 2025 to oversee the Americas commercial organization and lead business strategy and execution for its global Knees, Hips, S.E.T. and Data, Technology, and Enabling Solutions units. "Kevin is an incredible addition to our leadership team at an e
WARSAW, Ind., March 6, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Kristen Cardillo as Senior Vice President, Chief Communications Officer. Reporting to President and CEO Ivan Tornos, Ms. Cardillo will join the Company on March 10, 2025, to lead Zimmer Biomet's global communications strategy, enhancing engagement with key stakeholders and amplifying the Company's position as a leader in MedTech. "Kristen's expertise in shaping compelling corporate narratives and leading high-impac
SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
SC 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
WARSAW, Ind., Aug. 27, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2025. The cash dividend of $0.24 per share is payable on or about October 31, 2025 to stockholders of record as of the close of business on September 30, 2025. About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health.
Second quarter net sales of $2.077 billion increased 7.0% on a reported basis, 5.4% on a constant currency1 basis and 2.8% on an organic constant currency1 basisSecond quarter diluted earnings per share were $0.77; adjusted1 diluted earnings per share were $2.07, an increase of 3.0%Company tightens full-year 2025 reported, constant currency1 and organic constant currency1 revenue growth guidance to 6.7% - 7.7%, 6.2% - 7.2% and 3.5% - 4.5%, respectively, and increases adjusted1 earnings per share financial guidance to $8.10 - $8.30WARSAW, Ind., Aug. 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended June 30, 2025. T
WARSAW, Ind., July 9, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its second quarter earnings conference call will be webcast on Thursday, August 7, 2025 at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call. Individuals in the U.S. and Canada who wish to dial into the conference call may do so